Cargando…
Bisphosphonate Treatment Beyond 5 Years and Hip Fracture Risk in Older Women
IMPORTANCE: Clinical trials have demonstrated the antifracture efficacy of bisphosphonate drugs for the first 3 to 5 years of therapy. However, the efficacy of continuing bisphosphonate for as long as 10 years is uncertain. OBJECTIVE: To examine the association of discontinuing bisphosphonate at stu...
Autores principales: | Izano, Monika A., Lo, Joan C., Adams, Annette L., Ettinger, Bruce, Ott, Susan M., Chandra, Malini, Hui, Rita L., Niu, Fang, Li, Bonnie H., Neugebauer, Romain S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436954/ https://www.ncbi.nlm.nih.gov/pubmed/33284336 http://dx.doi.org/10.1001/jamanetworkopen.2020.25190 |
Ejemplares similares
-
Determinants of Oral Bisphosphonate Use Beyond 5 Years
por: Izano, Monika A., et al.
Publicado: (2020) -
Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years
por: Lo, Joan C., et al.
Publicado: (2020) -
OR03-4 Atypical Femur Fracture Incidence Increases with Duration of Bisphosphonate Exposure
por: Lo, Joan, et al.
Publicado: (2019) -
SAT-534 How Has Bisphosphonate Prescribing Changed in the Past Decade for Primary Fracture?
por: Yang, Betsy, et al.
Publicado: (2019) -
MON-510 Progression of Atypical Femur Stress Fracture after Discontinuation of Bisphosphonate Therapy
por: Gu, Kristine, et al.
Publicado: (2019)